In a pooled analysis of data of 31 RCTs measuring the effect of CCBs  on stroke  , CCBs  reduced stroke more than placebo and β-adrenergic blockers , but were not different than ACEIs and diuretics .
BACKGROUND Hypertension is a major risk factor for the development of stroke .
It is well known that lowering blood pressure decreases the risk of stroke in people with moderate to severe hypertension .
However , the specific effects of calcium channel blockers ( CCBs ) against stroke in patients with hypertension as compared to no treatment and other antihypertensive drug classes are not known .
Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial
Background —Most cardiovascular events associated with hypertension are complications of atherosclerosis . Some antihypertensive agents influence experimental models of atherosclerosis through mechanisms independent of blood pressure lowering . Methods and Results —The European Lacidipine Study on Atherosclerosis ( ELSA ) was a r and omized , double-blind trial in 2334 patients with hypertension that compared the effects of a 4-year treatment based on either lacidipine or atenolol on an index of carotid atherosclerosis , the mean of the maximum intima-media thicknesses ( IMT ) in far walls of common carotids and bifurcations ( CBMmax ) . This index has been shown by epidemiological studies to be predictive of cardiovascular events . A significant ( P < 0.0001 ) effect of lacidipine was found compared with atenolol , with a treatment difference in 4-year CBMmax progression of −0.0227 mm ( intention-to-treat population ) and −0.0281 mm ( completers ) . The yearly IMT progression rate was 0.0145 mm/y in atenolol-treated and 0.0087 mm/y in lacidipine-treated patients ( completers , 40 % reduction;P = 0.0073 ) . Patients with plaque progression were significantly less common , and patients with plaque regression were significantly more common in the lacidipine group . Clinic blood pressure reductions were identical with both treatments , but 24-hour ambulatory systolic/diastolic blood pressure changes were greater with atenolol ( −10/−9 mm Hg ) than with lacidipine ( −7/−5 mm Hg ) . No significant difference between treatments was found in any cardiovascular events , although the relative risk for stroke , major cardiovascular events , and mortality showed a trend favoring lacidipine . Conclusion —The greater efficacy of lacidipine  on carotid IMT progression and number of plaques per patient , despite a smaller ambulatory blood pressure reduction , indicates an antiatherosclerotic action of lacidipine independent of its antihypertensive action
In a pooled analysis of data of 31 RCTs measuring the effect of CCBs  on stroke  , CCBs  reduced stroke more than placebo and β-adrenergic blockers , but were not different than ACEIs and diuretics .
BACKGROUND Hypertension is a major risk factor for the development of stroke .
It is well known that lowering blood pressure decreases the risk of stroke in people with moderate to severe hypertension .
However , the specific effects of calcium channel blockers ( CCBs ) against stroke in patients with hypertension as compared to no treatment and other antihypertensive drug classes are not known .